drugset / Trial / NCT05334693
Expanded Haploidentical Natural Killer Cells as Consolidation Strategy for Children/Young Adults With AML
Phase 1/2
Recruiting
15 enrolled
Belarusian Research Center for Pediatric Oncology, Hematology and Immunology
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to estimate the efficacy of immunotherapy with ex vivo expanded haploidentical NK cells as consolidation therapy for children/young adults with intermediate risk AML.
Timeline
- Start
- 2021-11-01
- Primary completion
- 2025-12
- Completion
- 2026-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Expanded haploidentical NK cells | Cell therapy | 3e+07 cells/kg | Intravenous |
| Subject | Expanded haploidentical NK cells | Cell therapy | 1e+08 cells/kg | Intravenous |